Kymera Investor Day Presentation Deck
KT-253 is a Potent MDM2 Degrader and a Best-in-Class p53 Stabilizer
with Potential to Treat Numerous p53 WT Tumors
●
●
●
●
●
KT-253 inhibits tumor cell growth with picomolar potency and is more than 200-fold more
potent than clinically active MDM2 small molecule inhibitors
KT-253, unlike small molecule inhibitors, blocks the feedback loop which up-regulates
MDM2 production and in doing so more effectively stabilizes the tumor suppressor p53
Short term high exposures of KT-253 are enough to induce apoptosis in cell lines and in
vivo xenografts, which ensures high activity and improved therapeutic index vs SMI's
Broad franchise opportunities available for this mechanism (p53 WT is present in >50%
tumors), Kymera is focused on indications with specific sensitivity to degrader mechanism,
such as AML, Uveal melanoma and others through a biomarker strategy
Projected IND filing in 2022
KYMERA
©2021 KYMERA THERAPEUTICS, INC.
KYMERA R&D DAY - December 16th, 2021
PAGE 84View entire presentation